Breaking news from “The Pink Sheet” DAILY
Executive Summary
Visit 1www.ThePinkSheetDAILY.com for coverage of the latest developments in the pharmaceutical industry, including the failure of Genta's Genasense in a Phase III multiple myeloma trial and Express Scripts' expectations to profit from new generics in 2005. To sign up for a free trial of "The Pink Sheet" DAILY, visit our website or call customer service at 800-332-2181...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.